VIDEO Round-Up: BBHIC 2018

This year’s annual Bloom Burton & Co., Healthcare Investor Conference (BBHIC), which took place May 2-3 in Toronto hosted approximately 60 of Canada’s premier publicly-traded and venture-backed private companies with the most promising pre-venture companies in the healthcare industry.

The event brought investors and healthcare industry experts from all over the world who are interested in developments from the latest Canadian and US-based healthcare companies. The experts shared their unique knowledge through company presentations, analyst panels, keynote addresses and more to help investors and other experts alike learn more about the industry.

The Investing News Network (INN) was there for the entire conference and spoke with nine management teams from companies attending the event. Here is INN’s full recap of the interviews from the conference, for everything investors need to know about the current state of healthcare industry.

Resverlogix CEO Discusses Phase 3 BETonMACE Clinical Trial

CEO of Resverlogix (TSX:RVX) Don McCaffrey discusses recent financing in accordance to the company’s cardiovascular Phase 3 BETonMACE clinical trial set to end by the end of the year and what kind of an impact the company’s new drug could have for MACE (Major Adverse Cardiac Events) patients.

Aptose Provides Molecule Update and Q1 Financial Results

INN spoke with Aptose’s (NASDAQ:APTO; TSX:APS) president and CEO, William Rice and vice-president and Chief Financial Officer, Greg Chow to gain a better understanding of the company’s pipeline update, previous clinical hold—which will soon be returning to the clinic—and first quarter financial results.

Antibe Therapeutics Looking for More Licensing Deals

Antibe Therapeutics (TSXV:ATE, OTCQB:ATBPF) CEO and president Daniel Legault spoke to INN about how his company is changing the largest category of drugs globally. He also discussed what investors can look forward to in the coming year, including possible licensing deals.

New CEO and President of Acerus Shares Company’s Future Plans

Acerus’ (TSX:ASP) CEO Edward Guiditis shared the company is exploring global opportunities to expand. “From what we’ve seen in the last three to four months, [the share price] now has clear momentum beginning to build, trading at about two times what it was almost three months ago,” Guiditis said.

Providing Non-Exclusive Licenses Makes Zymeworks “Lucky,” Says CEO

“The field is extremely competitive because the need for breast cancer and gastric cancer is so great and unmet so being in a competitive field is a good thing,” Zymeworks (NYSE:ZYME; TSX:ZYME) CEO Ali Tehrani said. Tehrani also discussed to companies many non-exclusive licenses with big pharma companies and more.

Crescita’s US Prescription Product is “Launching Shortly,” says CEO

INN spoke with Crescita Therapeutics’ (TSX:CTX)president and CEO, Serge Verreault about the company’s soon-to-be US launched Pliaglis, it’s market potential, other licensing and more for this relatively new company—which is just two years old as of March 2016.

Pediapharm CEO Projects to Reach CA$35 Million in Revenue

Though Pediapharm (TSXV:PDP; OTCQB:PDDPF) now has a decently sized increase in revenue from its recently approved products, the company isn’t done with licensing. “Our business plan is projecting about $30 to $35 million in revenue with our current marketed products,” Pediapharm CEO Sylvain Chrétien told INN.

Medicenna Receives Amendment to Revamp Clinical Trial

Taking a large stance on glioblastoma, Medicenna’s (TSX:MDNA) CEO Fahar Merchant said the recent clinical trial amendment should allows patients to stay in the trial longer so patients don’t leave prematurely. Merchant explained how the company’s glioblastoma drug candidate is different for others, what kind of an impact it may have and more.

Don’t forget to follow us @INN_LifeScience for real-time news updates!

Securities Disclosure: I, Gabrielle Lakusta, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.